当前位置: 首页 >> 检索结果
4583. Mitapivat versus Placebo for Pyruvate Kinase Deficiency.
作者: Hanny Al-Samkari.;Frédéric Galactéros.;Andreas Glenthøj.;Jennifer A Rothman.;Oliver Andres.;Rachael F Grace.;Marta Morado-Arias.;D Mark Layton.;Koichi Onodera.;Madeleine Verhovsek.;Wilma Barcellini.;Satheesh Chonat.;Malia P Judge.;Erin Zagadailov.;Rengyi Xu.;Peter Hawkins.;Vanessa Beynon.;Sarah Gheuens.;Eduard J van Beers.; .
来源: N Engl J Med. 2022年386卷15期1432-1442页
Pyruvate kinase deficiency is a rare, hereditary, chronic condition that is associated with hemolytic anemia. In a phase 2 study, mitapivat, an oral, first-in-class activator of erythrocyte pyruvate kinase, increased the hemoglobin level in patients with pyruvate kinase deficiency.
4584. Rilzabrutinib, an Oral BTK Inhibitor, in Immune Thrombocytopenia.
作者: David J Kuter.;Merlin Efraim.;Jiri Mayer.;Marek Trněný.;Vickie McDonald.;Robert Bird.;Thomas Regenbogen.;Mamta Garg.;Zane Kaplan.;Nikolay Tzvetkov.;Philip Y Choi.;A J Gerard Jansen.;Milan Kostal.;Ross Baker.;Jaromir Gumulec.;Eun-Ju Lee.;Ilona Cunningham.;Isaac Goncalves.;Margaret Warner.;Ralph Boccia.;Terry Gernsheimer.;Waleed Ghanima.;Olga Bandman.;Regan Burns.;Ann Neale.;Dolca Thomas.;Puneet Arora.;Beiyao Zheng.;Nichola Cooper.
来源: N Engl J Med. 2022年386卷15期1421-1431页
Rilzabrutinib, an oral, reversible covalent inhibitor of Bruton's tyrosine kinase, may increase platelet counts in patients with immune thrombocytopenia by means of dual mechanisms of action: decreased macrophage (Fcγ receptor)-mediated platelet destruction and reduced production of pathogenic autoantibodies.
4585. Nonoperative or Surgical Treatment of Acute Achilles' Tendon Rupture.
作者: Ståle B Myhrvold.;Espen F Brouwer.;Tor K M Andresen.;Karin Rydevik.;Madeleine Amundsen.;Wolfram Grün.;Faisal Butt.;Morten Valberg.;Svend Ulstein.;Sigurd E Hoelsbrekken.
来源: N Engl J Med. 2022年386卷15期1409-1420页
Whether surgical repair of an acute Achilles' tendon rupture by an open-repair or minimally invasive approach is associated with better outcomes than nonsurgical treatment is not clear.
4590. Fourth Dose of BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting.
作者: Ori Magen.;Jacob G Waxman.;Maya Makov-Assif.;Roni Vered.;Dror Dicker.;Miguel A Hernán.;Marc Lipsitch.;Ben Y Reis.;Ran D Balicer.;Noa Dagan.
来源: N Engl J Med. 2022年386卷17期1603-1614页
With large waves of infection driven by the B.1.1.529 (omicron) variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), alongside evidence of waning immunity after the booster dose of coronavirus disease 2019 (Covid-19) vaccine, several countries have begun giving at-risk persons a fourth vaccine dose.
4593. Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer.
作者: Patrick M Forde.;Jonathan Spicer.;Shun Lu.;Mariano Provencio.;Tetsuya Mitsudomi.;Mark M Awad.;Enriqueta Felip.;Stephen R Broderick.;Julie R Brahmer.;Scott J Swanson.;Keith Kerr.;Changli Wang.;Tudor-Eliade Ciuleanu.;Gene B Saylors.;Fumihiro Tanaka.;Hiroyuki Ito.;Ke-Neng Chen.;Moishe Liberman.;Everett E Vokes.;Janis M Taube.;Cecile Dorange.;Junliang Cai.;Joseph Fiore.;Anthony Jarkowski.;David Balli.;Mark Sausen.;Dimple Pandya.;Christophe Y Calvet.;Nicolas Girard.; .
来源: N Engl J Med. 2022年386卷21期1973-1985页
Neoadjuvant or adjuvant chemotherapy confers a modest benefit over surgery alone for resectable non-small-cell lung cancer (NSCLC). In early-phase trials, nivolumab-based neoadjuvant regimens have shown promising clinical activity; however, data from phase 3 trials are needed to confirm these findings.
|